BioAlliance Pharma posts revenue of €4.1 million for the first half of 2009

• Loramyc® sales triple
• submission of a marketing authorization application for Setofilm® in Europe
• submission of a new drug application for Loramyc® in the USA
• significant progress in the supportive care portfolio
• OSEO funding validates the company's innovations

BioAlliance Pharma SA (Paris:BIO) (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today presented its consolidated half-year accounts to June 30, 2009.

The first half of 2009 was marked by several significant events that testify to the company’s progress:

• Submission of a new drug application (NDA) for Loramyc® to the United States Food and Drug Administration (FDA) and a marketing authorization application (MAA) for Setofilm® in Europe.
• The preparation of clinical trial applications (CTAs) for four products (fentanyl Lauriad® for cancer-related pain, AMEP™ in metastatic melanoma, clonidine Lauriad® for post-chemotherapy/post-radiotherapy mucitis and corticoid Lauriad® for erosive lichen planus) for submission by the end of 2009 or in early 2010.
• Progression and completion of recruitment in the first Phase III clinical trial of acyclovir Lauriad® in labial herpes (results expected in Q3 2009).
• Promising preclinical results for the company's programs in cancer (AMEP^TM and irinotecan Transdrug®) and AIDS (HIV integrase inhibitor).
• Receipt of €6.4 million in funding from OSEO (the French state innovation agency) for two cancer programs (AMEP^TM and Zyxine).

Commenting on BioAlliance Pharma's performance in the first half of 2009, President and CEO Dominique Costantini said: “Our first product, Loramyc®, is continuing to make progress, with steadily growing sales in France and submission of an NDA for marketing authorization in the United States, which will constitute a key milestone in commercial and financial terms. In the first half of 2010, we should be able to commercialize our second product, Setofilm®, which is currently being registered in 16 countries across Europe. Loramyc® (for the treatment of oropharyngeal candidiasis (OPC) in immune-compromised patients) and Setofilm® (for the treatment of post-chemotherapy and post-radiotherapy nausea and vomiting) are spearheading the high-quality supportive care franchise that BioAlliance is building. With two other products (fentanyl Lauriad® and clonidine Lauriad®) set to enter the clinic before the end of the year, BioAlliance will be able to offer a therapeutic arsenal in a field with many unmet needs and in which innovative approaches will significantly improve patient care. These are significant assets for attracting new corporate partners notably in Europe - a strategic objective for the company”.

Chief Financial Officer Nicolas Fellmann added: “We are very proud to have obtained €6.4 million in OSEO funding in the field of invasive cancers for our AMEP^TM and Zyxine programs. The grant will part-finance the product development through to market launch. Furthermore, this non-dilutive funding reinforces our short- and medium-term cash position and fits well with other initiatives, such as the Seroplex® co-promotion agreement that we signed with Lundbeck for the second half of the year”.

Analysis of the H1 2009 accounts

Revenues for the first half of 2009 amounted to €4.1 million. In France, Loramyc® posted sales of €0.9 million – a threefold increase on the €0.3 million generated in the first half of 2008. Besides revenues include €3.2 million received under the terms of Loramyc® out-licensing agreements.

In addition to R&D expenditure of €5.2 million, the operating loss of €9 million includes the following items:

• Promotional expenses related to the commercialization of Loramyc® in France.
• A €1.1 million research tax credit (a similar amount to that accounted for during H1 2008).
• Various general and administrative expenses, including intellectual property costs and those related to the ongoing litigation with SpePharm/SpeBio and Eurofins. As of June 30, 2009, BioAlliance Pharma had not made any provisions for potential liabilities related to this litigation.
• IFRS accounting adjustments, including a €0.4 million expense related to the warrants, stock options and free shares awarded by the company (IFRS 2).

The accounts show a financial profit of €0.1 million, compared with €1.1 million in 2008. These amounts correspond mainly to revenue from the sale of short-term investment products used by the company to manage its cash reserves. The significant year-on-year drop was due to both a decrease in available cash reserves and the sharp fall in money market interest rates.

The net loss for the half-year was €8.8 million, versus a loss of €7.9 million for the equivalent period in 2008.

Available cash and cash equivalents stood at €22.1 million as at June 30, 2009, versus €31.7 million as at December 31, 2008. This €9.6 million decrease is essentially due to R&D investments and promotional efforts related to the commercialization of Loramyc®. During the first half of 2009, BioAlliance Pharma also paid $1.25 million on filing of the NDA for Loramyc® in the United States, the repayment of which will take place during the second half of 2009. Lastly, during the first half of 2009, the company obtained full reimbursement of the research tax credit owed to it for the period 2004-2008, which amounted to a total of €4.6 million.